Maravai Lifesciences Holdings Inc Stock

$7.52-0.24 (-3.09%)
Updated Jun 14, 2024
MRVI Price
Fair Value Price
Market Cap
52 Week Low
52 Week High
Dividend Yield
Gross Margin
Operating Margin
Profit Margin
Debt to Equity
Operating Cash Flow
Next Earnings
Aug 5, 2024
Next Dividend

MRVI Overview

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MRVI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

MRVI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MRVI is good value based on its book value relative to its share price (4.61x), compared to the US Biotechnology industry average (6.25x)
P/B vs Industry Valuation
MRVI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MRVI due diligence checks available for Premium users.

Be the first to know about important MRVI news, forecast changes, insider trades & much more!



MRVI price to earnings (PE)

For valuing profitable companies with steady earnings

MRVI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
MRVI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

MRVI's financial health

Profit margin

Net Income
Profit Margin
MRVI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MRVI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Debt to equity
MRVI's short-term assets ($667.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MRVI's short-term assets ($667.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MRVI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

MRVI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

MRVI vs Biotech Stocks

TickerMarket Cap1d %P/EP/B

Maravai Lifesciences Holdings Stock FAQ

What is Maravai Lifesciences Holdings's quote symbol?

(NASDAQ: MRVI) Maravai Lifesciences Holdings trades on the NASDAQ under the ticker symbol MRVI. Maravai Lifesciences Holdings stock quotes can also be displayed as NASDAQ: MRVI.

If you're new to stock investing, here's how to buy Maravai Lifesciences Holdings stock.

What is the 52 week high and low for Maravai Lifesciences Holdings (NASDAQ: MRVI)?

(NASDAQ: MRVI) Maravai Lifesciences Holdings's 52-week high was $13.97, and its 52-week low was $4.52. It is currently -46.17% from its 52-week high and 66.37% from its 52-week low.

How much is Maravai Lifesciences Holdings stock worth today?

(NASDAQ: MRVI) Maravai Lifesciences Holdings currently has 251,924,898 outstanding shares. With Maravai Lifesciences Holdings stock trading at $7.52 per share, the total value of Maravai Lifesciences Holdings stock (market capitalization) is $1.89B.

Maravai Lifesciences Holdings stock was originally listed at a price of $29.85 in Nov 20, 2020. If you had invested in Maravai Lifesciences Holdings stock at $29.85, your return over the last 3 years would have been -74.81%, for an annualized return of -36.84% (not including any dividends or dividend reinvestments).

How much is Maravai Lifesciences Holdings's stock price per share?

(NASDAQ: MRVI) Maravai Lifesciences Holdings stock price per share is $7.52 today (as of Jun 14, 2024).

What is Maravai Lifesciences Holdings's Market Cap?

(NASDAQ: MRVI) Maravai Lifesciences Holdings's market cap is $1.89B, as of Jun 15, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Maravai Lifesciences Holdings's market cap is calculated by multiplying MRVI's current stock price of $7.52 by MRVI's total outstanding shares of 251,924,898.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.